Chello P L, McQueen C A, DeAngelis L M, Bertino J R
Cancer Res. 1976 Jul;36(7 PT 1):2442-9.
Roswell Park Memorial Institute 4265 human lymphoblasts were grown with three dihydrofolate reductase inhibitors: a 2,4-diaminopteridine, methotrexate; a 2,4-diaminoquinazoline, chlorasquin; and, a 2,4-diaminotriazine, triazinate. In the absence of inhibitor, dihydrofolate reductase activity increased to a peak at mid-log growth and then declined during the later growth stages. When cells were grown with 10(-8) M antifolate, cell growth was not affected, but dihydrofolate reductase activity (assayed at pH 7.0) remained at approximately initial levels throughout the growth cycle. This represented 60 to 70% less activity at the mid-log stage of growth, as compared to control cells. Dihydrofolate reductase activity in cells grown with 10(-8) M methotrexate, when assayed at pH 8.5, reached levels twice those in control cells. Enzyme activity in cells grown with 10(-8) M chlorasquin, when assayed at pH 8.5, was also higher than at pH 7.0, but it was not as high as that observed in methotrexate-treated cells. Activity in cells grown with 10(-8) M triazinate was approximately the same when assayed at either pH 7.0 or 8.5. At 10(-8) M, the three antifolates had no effect on the activities of thymidylate synthetase, thymidine kinase, serine trans-hydroxymethylase, 5,10-methylenetetrahydrofolate dehydrogenase, 10-formyltetrahydrofolate synthetase, and thymidylate kinase. However, when concentrations were used which completely inhibited growth (10(-7) to 10(-5) M methotrexate or chlorasuin; 10(-6) to 10(-5) M triazinate), dihydrofolate reductase was progressively inhibited, and there was a two- and a threefold elevation of thymidylate synthetase and thymidine kinase activity, respectively. Quantitatively, the elevation of either enzyme was similar over the range of growth-inhibitory concentrations studied. The activities of the other enzymes were unaffected. Methotrexate and chlorasquin inhibited thymidylate synthetase in a noncompetitive manner (with respect to 5,10-methylenetetrahydrofolate) with approximate Ki values of 4.5 X 10(-5) M and 4.9 X 10(-6) M, respectively. Triazinate, at 10(-3) M, had no significant effect on thymidylate synthetase activity. At 10(-3) M, the antifolates produced a negligible inhibition of thymidine kinase. Deoxyuridine 5'-monophosphate (10(-5) M) effectively protected thymidylate synthetase from heat inactivation in vitro. Dihydrofolate or 5,10-methylenetetrahydrofolate, at 10(-3) M, only partially protected thymidylate synthetase. Concentrations of methotrexate (10(-7) to 10(-6) M), chlorasquin (10(-7) M), and triazinate (10(-6) to 10(-5) M), which produced thymidylate synthetase elevation in vivo, did not protect the enzyme from heat inactivation in vitro. Methotrexate at 10(-5) M and chlorasquin at 10(-6) M gave slight protection. Thymidine kinase was stabilized only by thymidine.
罗斯威尔帕克纪念研究所使用三种二氢叶酸还原酶抑制剂培养了4265个人类淋巴母细胞:一种2,4 - 二氨基蝶啶,即甲氨蝶呤;一种2,4 - 二氨基喹唑啉,即氯喹嗪;还有一种2,4 - 二氨基三嗪,即三嗪酸盐。在没有抑制剂的情况下,二氢叶酸还原酶活性在对数生长期中期增加到峰值,然后在生长后期下降。当细胞用10^(-8) M抗叶酸剂培养时,细胞生长不受影响,但二氢叶酸还原酶活性(在pH 7.0下测定)在整个生长周期中保持在大约初始水平。与对照细胞相比,这代表在对数生长期中期活性降低了60%至70%。用10^(-8) M甲氨蝶呤培养的细胞,在pH 8.5下测定时,二氢叶酸还原酶活性达到对照细胞的两倍。用10^(-8) M氯喹嗪培养的细胞,在pH 8.5下测定时,酶活性也高于pH 7.0时,但不如甲氨蝶呤处理的细胞高。用10^(-8) M三嗪酸盐培养的细胞,在pH 7.0或8.5下测定时活性大致相同。在10^(-8) M时,这三种抗叶酸剂对胸苷酸合成酶、胸苷激酶、丝氨酸转羟甲基酶、5,10 - 亚甲基四氢叶酸脱氢酶、10 - 甲酰四氢叶酸合成酶和胸苷酸激酶的活性没有影响。然而,当使用完全抑制生长的浓度(10^(-7)至10^(-5) M甲氨蝶呤或氯喹嗪;10^(-6)至10^(-5) M三嗪酸盐)时,二氢叶酸还原酶被逐渐抑制,胸苷酸合成酶和胸苷激酶活性分别升高了两倍和三倍。从数量上看,在所研究的生长抑制浓度范围内,这两种酶的升高情况相似。其他酶的活性不受影响。甲氨蝶呤和氯喹嗪以非竞争性方式(相对于5,10 - 亚甲基四氢叶酸)抑制胸苷酸合成酶,其近似Ki值分别为4.5×10^(-5) M和4.9×10^(-6) M。10^(-3) M的三嗪酸盐对胸苷酸合成酶活性没有显著影响。在10^(-3) M时,抗叶酸剂对胸苷激酶产生的抑制作用可忽略不计。脱氧尿苷5'-单磷酸(10^(-5) M)在体外有效地保护胸苷酸合成酶免受热失活。10^(-3) M的二氢叶酸或5,10 - 亚甲基四氢叶酸仅部分保护胸苷酸合成酶。在体内使胸苷酸合成酶升高的甲氨蝶呤浓度(10^(-7)至10^(-6) M)、氯喹嗪浓度(10^(-7) M)和三嗪酸盐浓度(10^(-6)至10^(-5) M),在体外不能保护该酶免受热失活。10^(-5) M的甲氨蝶呤和10^(-6) M的氯喹嗪有轻微保护作用。胸苷激酶仅由胸苷稳定。